|
SNDX-5613 zeigt Remissionen bei Leukämiepatienten
ir.syndax.com/news-releases/...erim-data-demonstrating-robust
Zahlen für Q2/21
- Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated results from Phase 1 portion anticipated in 4Q21
- Enrollment ongoing in global pivotal AGAVE-201 trial of axatilimab in cGVHD; updated results from Phase 1/2 trial anticipated in 4Q21
ir.syndax.com/news-releases/...-second-quarter-2021-financial
Kollaboration mit Incyte
www.fiercebiotech.com/biotech/...en-chronic-graft-versus-host
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 48 | Aktie 2018? | warkla2 | warkla2 | 09.02.24 16:16 |